MapLight Therapeutics Inc. (MPLT) completed its initial public offering of 16,962,500 shares of common stock at $17.00 per share, including the full exercise of underwriters’ op ...

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating ...

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the ...

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system ...

Zag Bio announced the company’s launch with a $80 million financing round, which includes a recently closed Series A ...

USA-based CNS specialist MapLight Therapeutics successfully made its public debut on Sunday evening, raising more than $250 ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

The health sector faces significant changes as Poland reports an outbreak of bluetongue disease, WOAH confirms. Meanwhile, ...

Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ambitions got a big boost from the biotech’s market debut.

In a bold move against a backdrop of federal uncertainty, MapLight Therapeutics has gone public, raising $251 million in its ...

MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...